Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 211

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease

Open access
Hall, Zoe, Bond, Nicholas J., Ashmore, Tom, Sanders, Francis, Ament, Zsuzsanna, Wang, Xinzhu, Murray, Andrew J., Bellafante, Elena, Virtue, Sam, Vidal‐Puig, Antonio, Allison, Michael, Davies, Susan E., Koulman, Albert, Vacca, Michele, Griffin, Julian L. · 2017 · Hepatology

Abstract

Nonalcoholic fatty liver disease (NAFLD) can progress from simple steatosis (i.e., nonalcoholic fatty liver [NAFL]) to nonalcoholic steatohepatitis (NASH), cirrhosis, and cancer. Currently, the driver for this progression is not fully understood; in particular, it is not known how NAFLD and its early progression affects the distribution of lipids in the liver, producing lipotoxicity and inflammation. In this study, we used dietary and genetic mouse models of NAFL and NASH and translated the results to humans by correlating the spatial distribution of lipids in liver tissue with disease progression using advanced mass spectrometry imaging technology. We identified several lipids with distinct zonal distributions in control and NAFL samples and observed partial to complete loss of lipid zonation in NASH. In addition, we found increased hepatic expression of genes associated with remodeling the phospholipid membrane, release of arachidonic acid (AA) from the membrane, and production of eicosanoid species that promote inflammation and cell injury. The results of our immunohistochemistry analyses suggest that the zonal location of remodeling enzyme LPCAT2 plays a role in the change in spatial distribution for AA‐containing lipids. This results in a cycle of AA‐enrichment in pericentral hepatocytes, membrane release of AA, and generation of proinflammatory eicosanoids and may account for increased oxidative damage in pericentral regions in NASH. Conclusion: NAFLD is associated not only with lipid enrichment, but also with zonal changes of specific lipids and their associated metabolic pathways. This may play a role in the heterogeneous development of NAFLD. (H epatology 2017;65:1165‐1180)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.28953

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 37

  1. 2014, Pathological features of fatty liver disease, Gastroenterology, 147, 754, 10.1053/j.gastro.2014.07.056 · DOI · Paper page
  2. 2013, From NAFLD to NASH to cirrhosis‐new insights into disease mechanisms, Nat Rev Gastroenterol Hepatol, 10, 627, 10.1038/nrgastro.2013.149 · DOI · Paper page
  3. 2015, Fatty acid and glucose sensors in hepatic lipid metabolism: implications in NAFLD, Semin Liver Dis, 35, 250, 10.1055/s-0035-1562945 · DOI
  4. 2016, De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose, Biol Rev, 91, 452, 10.1111/brv.12178 · DOI · Paper page
  5. 2015, Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis, J Lipid Res, 56, 185, 10.1194/jlr.P055640 · DOI · Paper page
  6. 2013, Prediction of non‐alcoholic fatty‐liver disease and liver fat content by serum molecular lipids, Diabetologia, 56, 2266, 10.1007/s00125-013-2981-2 · DOI · Paper page
  7. 2014, Zonation of glucose and fatty acid metabolism in the liver: mechanism and metabolic consequences, Biochimie, 96, 121, 10.1016/j.biochi.2013.06.007 · DOI · Paper page
  8. 2011, MALDI imaging of lipid biochemistry in tissues by mass spectrometry, Chem Rev, 111, 6491, 10.1021/cr200280p · DOI · Paper page
  9. 2015, Current state and future challenges of mass spectrometry imaging for clinical research, Anal Chem, 87, 6426, 10.1021/acs.analchem.5b00416 · DOI
  10. 2013, Matrix‐assisted laser desorption ionization imaging mass spectrometry: in situ molecular mapping, Biochemistry, 52, 3818, 10.1021/bi301519p · DOI
  11. 2013, Differential intrahepatic phospholipid zonation in simple steatosis and nonalcoholic steatohepatitis, PLoS One, 8, e57165, 10.1371/journal.pone.0057165 · DOI
  12. 2009, Chemical imaging on liver steatosis using synchrotron infrared and ToF‐SIMS microspectroscopies, PLoS One, 4, e7408, 10.1371/journal.pone.0007408 · DOI
  13. 2009, In situ lipidomic analysis of nonalcoholic fatty liver by cluster TOF‐SIMS imaging, Anal Chem, 81, 2823, 10.1021/ac900045m · DOI · Paper page
  14. 2013, Hepatic‐specific activation of peroxisome proliferator‐activated receptor γ coactivator‐1β protects against steatohepatitis, Hepatology, 57, 1343, 10.1002/hep.26222 · DOI
  15. 2012, Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients, Hepatology, 56, 1751, 10.1002/hep.25889 · DOI · Paper page
  16. 2007, LMSD: LIPID MAPS structure database, Nucleic Acids Res, 35, D527, 10.1093/nar/gkl838 · DOI · Paper page
  17. 1998, Formation of lithiated adducts of glycerophosphocholine lipids facilitates their identification by electrospray ionization tandem mass spectrometry, J Am Soc Mass Spectrom, 9, 516, 10.1016/S1044-0305(98)00012-9 · DOI · Paper page
  18. 1957, A simple method for the isolation and purification of total lipids from animal tissues, J Biol Chem, 226, 497, 10.1016/S0021-9258(18)64849-5 · DOI · Paper page
  19. 2016, Myc expression drives aberrant lipid metabolism in lung cancer, Cancer Res, 76, 4608, 10.1158/0008-5472.CAN-15-3403 · DOI
  20. 2008, Visualization of GC/TOF‐MS‐based metabolomics data for identification of biochemically interesting compounds using OPLS class models, Anal Chem, 80, 115, 10.1021/ac0713510 · DOI · Paper page
  21. 2002, Orthogonal projections to latent structures (o‐PLS), J Chemometrics, 16, 119, 10.1002/cem.695 · DOI · Paper page
  22. 2011, imzML: imaging mass spectrometry markup language: a common data format for mass spectrometry imaging, Methods Mol Biol, 696, 205, 10.1007/978-1-60761-987-1_12 · DOI
  23. 2012, Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, World J Gastroenterol, 18, 2300, 10.3748/wjg.v18.i19.2300 · DOI · Paper page
  24. 2012, Laboratory animals as surrogate models of human obesity, Acta Pharmacol Sin, 33, 173, 10.1038/aps.2011.203 · DOI · Paper page
  25. 2015, Comprehensive metabolic profiling of age‐related mitochondrial dysfunction in the high‐fat‐fed ob/ob mouse heart, J Proteome Res, 14, 2849, 10.1021/acs.jproteome.5b00128 · DOI
  26. 2015, Adipose tissue fatty acid chain length and mono‐unsaturation increases with obesity and insulin resistance, Sci Rep, 5, 18366, 10.1038/srep18366 · DOI
  27. 2014, Role of adipose tissue in methionine–choline‐deficient model of non‐alcoholic steatohepatitis (NASH), Biochim Biophys Acta, 1842, 959, 10.1016/j.bbadis.2014.02.012 · DOI
  28. 2015, Mouse models of diet‐induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease, PLoS ONE, 10, e0127991, 10.1371/journal.pone.0127991 · DOI · Paper page
  29. 2011, Animal models in nonalcoholic steatohepatitis research: utility and clinical translation, Liver Int, 31, 440, 10.1111/j.1478-3231.2011.02463.x · DOI
  30. 2011, Animal models of nonalcoholic fatty liver disease, Nat Rev Gastroenterol Hepatol, 8, 35, 10.1038/nrgastro.2010.191 · DOI · Paper page
  31. 2010, Disruption of the 12/15‐lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease, Hepatology, 52, 1980, 10.1002/hep.23928 · DOI
  32. 2012, Group IVA phospholipase A2 participates in the progression of hepatic fibrosis, FASEB J, 26, 4111, 10.1096/fj.12-205625 · DOI
  33. 2009, Alleviation of high‐fat diet‐induced fatty liver damage in group IVA phospholipase A2‐knockout mice, PLoS One, 4, e8089, 10.1371/journal.pone.0008089 · DOI
  34. 2011, Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity, Nature, 473, 528, 10.1038/nature09968 · DOI · Paper page
  35. 2014, Diversity and function of membrane glycerophospholipids generated by the remodeling pathway in mammalian cells, J Lipid Res, 55, 799, 10.1194/jlr.R046094 · DOI · Paper page
  36. 2012, Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis, Hepatology, 56, 118, 10.1002/hep.25630 · DOI · Paper page
  37. 2002, Kupffer cell aggregation and perivenular distribution in steatohepatitis, Mod Pathol, 15, 699, 10.1097/01.MP.0000019579.30842.96 · DOI

Cited by

See all 211

Metadata

Authors
Hall, Z., Bond, N. J., Ashmore, T., Sanders, F., Ament, Z., Wang, X., Murray, A. J., Bellafante, E., Virtue, S., Vidal‐Puig, A., Allison, M., Davies, S. E., Koulman, A., Vacca, M., & Griffin, J. L.
Venue
Hepatology
Published
2017-02-06
Volume
65
Issue
4
Pages
1165-1180
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2553298154
Cited by
211
References
6
FWCI
16.36
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.